Transgene Announces Option for TG4010 Not Exercised
Moving forward with preparations for Phase 3 part of TIME trial as planned
Transgene to seek alternative development and commercialization partner
Conference call scheduled for April 29 at 9 AM CET
Strasbourg, France, April 28, 2014 - Transgene SA (NYSE-Euronext: TNG) today announced that Novartis has informed the Company that it will not exercise its option for the global development and commercialization rights to TG4010 MUC1 targeted cancer immunotherapy. As a result, Transgene retains all rights to the program.
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer